Trials / Completed
CompletedNCT04432688
The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,192 (actual)
- Sponsor
- Sumitomo Pharma (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
It's a prospective, non-interventional, observational Post-marketing Surveillance..
Detailed description
It's a prospective, non-interventional, observational Post-marketing Surveillance, the aim of the surveillance is to observe the safety and overall effectiveness of Latuda® in the treatment of Chinese patients with schizophrenia for 12 weeks in real clinical practice, as well as the dose of Latuda® for monotherapy or combination therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lurasidone HCl | This is a non-interventional, observational study |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2023-03-18
- Completion
- 2023-06-18
- First posted
- 2020-06-16
- Last updated
- 2024-04-18
Locations
7 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04432688. Inclusion in this directory is not an endorsement.